I'm pretty sure you read this backwards - Only 27%
Post# of 148150
Yes, this a while ago, and only critical patients are intubated. That said, leronlimab is clearly running the trial of the sickest, often taking patients too risky under other drugs, and with no upper age limit.
There are lots of ways to keep the stat significance numbers in your head.
I start with the assumption that leronlimab will cut the death rate in half - implying the same number of total deaths as the control arm.
Then, with 130 treatment/65 control:
if P(die|control) > 25% (16 deaths), then P<.05 two sided
if P(die|control) = 50% (32 deaths), then P<.0001 two sided
Again, Wolfram diff of binomials - unilikely the actual test.